A Phrase 3, Randomized, Open-label (Sponsor Blinded) Study of Relatlimab-nivolumab Fixed dose Combination Versus Regorafenib or Trifluridine + Tripiracil (TAS-102) for Participants with Later-lines of Metastatic Colorectal Cancer

  • Lau, David (Primary Chief Investigator (PCI))
  • Frentzas, Sophia (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date13/06/22 → 28/06/27

Keywords

  • treatment safety
  • treatment efficacy
  • colorectal cancer